Preclinical testing of three south American antivenoms against the venoms of five medically-important Peruvian snake venoms

G. D. Laing, A. Yarleque, A. Marcelo, E. Rodriguez, D. A. Warrell, R. D.G. Theakston

Research output: Contribution to journalArticlepeer-review

18 Scopus citations

Abstract

World Health Organization (WHO)-recommended preclinical in vivo and in vitro studies were carried out to compare the efficacy of Brazilian, Peruvian and Colombian antivenoms in neutralizing the venom toxins responsible for the lethal, haemorrhagic, necrotizing, coagulant and defibrinogenating effects of five medically-important Peruvian snake venoms. Overall, the Brazilian antivenom was found to be the most effective followed by the Peruvian and Colombian antivenoms. However, it was concluded that all three antivenoms would be acceptable for use in a randomised clinical trial in envenomed humans in Peru.

Original languageEnglish
Pages (from-to)103-106
Number of pages4
JournalToxicon
Volume44
Issue number1
DOIs
StatePublished - Jul 2004

Bibliographical note

Funding Information:
The authors gratefully acknowledge the financial support, advice and assistance of the British Council (Lima) without which it would not have been possible to carry out this study.

Keywords

  • In vitro tests
  • In vivo tests
  • Peru
  • South American antivenoms
  • World Health Organization

Fingerprint

Dive into the research topics of 'Preclinical testing of three south American antivenoms against the venoms of five medically-important Peruvian snake venoms'. Together they form a unique fingerprint.

Cite this